Table 4.
Week 12 AUC for MMTT variables
| Change from baseline to week 12 AUC (%) | AUC 0–120 min | AUC 0–180 min | ||
|---|---|---|---|---|
| Placebo | Evolocumab | Placebo | Evolocumab | |
| Total cholesterol | 1.7 (1.5) [128] | −30.9 (1.0)* [257] | 1.1 (2.9) [27] | −31.3 (2.3) [57] |
| LDL-C | −2.1 (−10.5, 10.5) [117] | −60.6 (−71.6, −39.9)* [235] | −2.7 (−5.8, 3.8) [25] | −59.7 (72.8, −37.6)* [53] |
| HDL-C | −0.5 (1.1) [128] | 8.7 (1.0)* [257] | 4.0 (2.4) [27] | 10.6 (2.3)* [57] |
| Non-HDL-C | 2.7 (2.0) [128] | −42.7 (1.3) [257] | 0.5 (3.7) [27] | −43.2 (2.8) [57] |
| Triacylglycerol | 4.6 (−13.0, 29.3) [128] | −13.4 (−26.6, 8.4)* [257] | −4.7 (−18.7, 36.3) [27] | −17.0 (−32.7, 7.1)* [57] |
| VLDL-C | 7.3 (3.0) [117] | −5.8 (2.4)* [239] | 6.8 (6.8) [25] | −8.3 (4.4) [55] |
| Chylomicron triacylglycerol | 6.9 (−19.9, 42.5) [96] | −12.8 (−33.8, 25.4)* [183] | −7.3 (−15.8, 23.0) [25] | −7.4 (−25.5, 26.1)* [44] |
| Chylomicron cholesterol | −1.8 (−16.7, 28.3) [97] | −19.7 (−34.1, 0.0)* [185] | −4.2 (−15.8, 28.3) [25] | −24.2 (−33.6, −5.4) [44] |
| ApoB-48 | 0.0 (−26.6, 31.6) [125] | −14.5 (−36.9, 18.2)* [252] | −0.7 (−26.2, 34.9) [26] | −8.5 (−36.3, 23.3) [59] |
| Plasma glucose | 2.5 (−9.6, 22.8) [129] | 2.6 (−9.0, 18.2) [257] | 7.5 (−8.0, 18.8) [27] | 6.6 (−8.5, 15.6) [60] |
| Insulin | 6.6 (−22.5, 50.0) [126] | 0.0 (−22.0, 29.1) [248] | 14.3 (−14.1, 53.4) [27] | 8.7 (−23.1, 40.6) [56] |
| Proinsulin | 6.7 (−18.1, 41.6) [128] | 0.0 (−22.4, 39.6) [260] | 5.9 (−11.7, 49.1) [28] | −2.7 (−26.5, 19.9) [62] |
| C-peptide | 4.1 (−13.8, 22.9) [125] | 2.0 (−12.4, 17.0) [243] | −0.1 (−5.6, 30.1) [25] | 2.4 (−18.4, 11.7) [55] |
| Glucagon | 2.8 (−22.4, 39.2) [120] | −0.1 (−20.4, 23.4) [242] | 0.5 (−18.9, 48.2) [25] | −3.3 (−23.3, 26.1) [57] |
| NEFA | −1.3 (−18.8, 21.3) [131] | −2.1 (−24.0, 26.7) [262] | 2.2 (−26.8, 28.6) [28] | −4.6 (−19.6, 15.3) [61] |
| IL-6 | −1.6 (−21.7, 17.4) [127] | −0.8 (−21.5, 29.5) [259] | 3.8 (−11.4, 31.0) [28] | −5.8 (−25.7, 30.9) [59] |
| Adiponectin | −0.8 (−12.9, 12.3) [130] | −2.1 (−16.0, 15.0) [262] | 1.7 (−11.6, 10.2) [28] | 1.8 (−8.5, 17.7) [61] |
All data presented are median (Q1, Q3) AUC [n], except for total cholesterol, HDL-C, non-HDL-C and VLDL-C, which are mean (SEM) AUC [n]
n, number of participants in the full analysis set who had MMTT timepoint (120 min) or extended-timepoint (180 min) assessments
*p<0.05 (nominal, post hoc, no multiplicity adjustment)